Clinical trials: PD-1 Inhibitors
Melanoma, Non-Small Cell Lung Cancer
POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors
This is a two-center, prospective continuously accruing longitudinal cohort study in patients with non-small cell lung carcinoma (NSCLC) or metastatic melanoma eligible for standard anti-PD-1 antibody treatment.
- Trial name
- POINTING (NCT04193956)
- Testing
- Standard-of-care procedures, Study procedures
- Where
- 2 sites in Netherlands
- Volunteers
- 3,500 people
- Sponsor
- University Medical Center Groningen
Hepatocellular Carcinoma
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection.
- Trial name
- NCT06248554
- Testing
- PD-1 Inhibitors
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Chen Xiaoping
Breast Cancer
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
- Trial name
- NCT06547476
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
The purpose of this study in to observe the effectiveness and safety of paclitaxel (albumin-bound type) combined with cisplatin, PD-1 inhibitor and IMRT in the treatment of locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04769076
- Testing
- Paclitaxel（Albumin-bound）
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
HER2 Positive Solid Tumors
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies
- Trial name
- NCT04460456
- Testing
- SBT6050, pembrolizumab, Cemiplimab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 58 people
- Sponsor
- Silverback Therapeutics
Melanoma (Skin Cancer), Melanoma Stage Stage IIIB
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
This study evaluates the impact of neoadjuvant Programmed cell death Protein 1 (PD-1)-based treatment regimens in patients with resectable stage IIIB-M1a cutaneous or unknown primary melanoma at high risk of relapse without…
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV
- Trial name
- NCT07740941
- Testing
- Pembrolizumab, Ipilimumab plus nivolumab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Intrahepatic Cholangiocarcinoma
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
This is a prospective, single-center, single-arm clinical study. It aims to evaluate the efficacy and safety of a new combination therapy as a first-line treatment for patients with advanced intrahepatic cholangiocarcinoma (ICC)…
- Trial name
- NCT07432568
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin, Lenvatinib, PD-1 Inhibitor
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Carcinoma, Cervix Carcinoma
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial…
- Trial name
- GYNET (NCT04652076)
- Testing
- NP137, Pembrolizumab, Paclitaxel
- Where
- 15 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- NETRIS Pharma
Advanced Malignant Solid Tumor
Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors
This study aims to evaluate the safety and tolerability of lattice radiation therapy in combination with PD-1/PD-L1 inhibitors for patients with advanced solid tumors and large tumors, and to assess its efficacy.
- Trial name
- NCT07865793
- Testing
- lattice radiotherapy and PD-1/PD-L1 inhibitors
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatitis B, Chronic
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
- Trial name
- OCTOPUS-1 (NCT05275023)
- Testing
- JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil
- Where
- 26 sites in Canada, Czechia and 6 more
- Volunteers
- 37 people
- Sponsor
- Janssen Research & Development, LLC
Soft Tissue Sarcoma, Bone Sarcoma
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
The purpose of this study is to determine whether nivolumab plus ipilimumab are effective and safe in the treatment of sarcoma and endometrial carcinoma patients with somatic deficient MMR as a selection tool.
- Conditions
- Soft Tissue Sarcoma, Bone Sarcoma, Chondrosarcoma, Gastrointestinal Stromal Sarcoma
- Trial name
- NCT02982486
- Testing
- Ipilimumab, Nivolumab
- Volunteers
- 60 people
- Sponsor
- Assaf-Harofeh Medical Center
Colorectal Cancer Metastatic
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal…
- Trial name
- NCT06547203
- Testing
- Cetuximab, Toripalimab, Irinotecan
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Large B-Cell, Diffuse, Transplantation
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL)…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
- Trial name
- NCT04789434
- Testing
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.
- Trial name
- NCT07034391
- Testing
- denosumab combined anti-PD-1 inhibitor with chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- China Medical University, China
Limited Stage Small Cell Lung Cancer
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.
- Trial name
- TIGOS-LS (NCT06773910)
- Testing
- BMS-986489, Durvalumab
- Where
- 34 sites in United States
- Volunteers
- 250 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer, Neoadjuvant Therapy
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody…
- Conditions
- Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
- Trial name
- NCT07359040
- Testing
- Ivonescimab, PD-1 Inhibitors
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
This multicenter retrospective-prospective cohort study evaluates predictive biomarker and tissue-pathology features for response to PD-1 inhibitor-based therapy in patients with squamous cell carcinoma (SCC).
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
- Trial name
- PB-PD1R-SCC (NCT07147361)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Cancer of Unknown Primary
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and…
- Trial name
- NCT04848597
- Testing
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University